ViroGates’ initial public offering of new shares was 141% oversubscribed.
As of June 26, 2018 ViroGates is listed on Nasdaq OMX First North in Denmark.
The Company’s offering of a minimum of 659,341 and a maximum of 824,175 newly issued shares at an offer price of
DKK 91 per share has been fully subscribed.
On that background, the final number of offer shares is 824,175, which will provide the Company with gross proceeds of
DKK 75.0 million.
The proceeds are to be deployed to intensify the continued commercial roll-out of the Company’s products and strengthen its product development, clinical documentation and global patent coverage.
The Company’s shares will be admitted to trading under the symbol “VIRO” (ISIN:DK0061030574) as of 26 June 2018.
More information to be found here; Investor – Announcements